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Erythromycin for the Treatment of Feeding
Intolerance in Preterm InfantsFeeding intolerance is a frequent problem among preterm
infants in intensive care. The condition usually manifests as
a large residue of food in the stomach at the next feed, and
may be associated with abdominal distension, intermittent
regurgitation or vomiting. Earlier feeding can assist normal
development of the gastrointestinal tract, and also avoid
health problems related to feeding by intravenous lines.
Slow progression to enteral feeding often predisposes
preterm infants to prolonged use of parenteral nutrition,
nosocomial infections, hepatic dysfunction, and prolonged
hospitalization.1
In this issue of Pediatrics and Neonatology, Ng et al2
report their finding that intermediate-dose erythromycin
(20 mg/kg/day) used as rescue treatment is associated with
quicker attainment of full enteral feeding and a body
weight 2500 g, shorter duration of the need for parenteral
nutrition, and less parenteral nutrition-associated chole-
stasis. Feeding intolerance is a result of ineffective, infre-
quent, uncoordinated bowel activity secondary to
immaturity of the gastrointestinal tract.3 Term infants
exhibit multiphasic cycles of intestinal motor activity,
termed migratory motor complex, during the interdigestive
period. Preterm infants of less than 32 weeks’ gestational
age lack the propagative phase III of the migrating motor
complex in the upper gastrointestinal tract.4 Their inter-
digestive activity consists of random periods of quiescence
and nonpropagated contractions. This functional immatu-
rity predisposes them to feeding intolerance.
The peptide motilin may initiate phase III activity of the
interdigestive migratory motor complex in the upper
gastrointestinal tract, regulate gastrointestinal motility, and
stimulate postprandial gastric muscle contractions and
gastric emptying.4,5 In-vitro studies have shown that eryth-
romycin is a motilin agonist.6 Erythromycin, a commonly
used macrolide antibiotic, acts as a nonpeptide motilin
agonist by binding to the motilin receptor and has been used
to facilitate enteral feeding in preterm infants. Various
treatment regimens, including prophylaxis versus rescue1875-9572/$36 Copyright ª 2012, Taiwan Pediatric Association. Publish
doi:10.1016/j.pedneo.2011.11.002treatment and low dose (3e15 mg/kg/day) versus high dose
(50 mg/day), have been investigated. The gastrointestinal
motor effects of erythromycin are well documented in clin-
ical studies and the use of erythromycin as a prokinetic agent
became fairly common in neonatal units.7 Themechanism by
which erythromycin enhances enteral feeding in preterm
infants is not completely known. Current evidence suggests
that its prokinetic action is mediated via the motilin
pathway.4 Erythromycin enhances the release of endogenous
motilin and stimulates cholinergic nerves of the gastroin-
testinal tract at the pre- and post-ganglionic levels, resulting
in the release of calcium and contraction of muscles of
the gut.
There is one major concern with the study by Ng et al.2
The intervention was not blinded from the clinical team,
raising the possibility that the choice of treatments
(including parenteral nutrition regimen and feeding
schedule) after randomization was biased by knowledge of
the allocation group. Although the role of erythromycin as
a prokinetic agent in preterm infants has been recently
investigated in a number of randomized control trials,
there remains much controversy concerning its efficacy in
promoting enteral feeding and possible adverse effect. The
Cochrane Collaboration concluded that there is insufficient
evidence to show benefit from erythromycin used in large
or small doses for the prevention or treatment of feeding
problems in premature infants.7 This is possibly because of
the varying dosages, times, routes, and duration of eryth-
romycin administration used in different studies.
Further studies are needed to investigate the patho-
physiologic mechanisms of functional gastrointestinal dys-
motility in preterm infants and only large-scale randomized
controlled trials will determine the efficacy and safety of
using macrolides for treating gastrointestinal dysmotility in
very preterm infants. Although no study has reported any
ominous adverse effects, neonatologists should be cautious
in their use of this class of drug in preterm infants with
functional gastrointestinal dysmotility.ed by Elsevier Taiwan LLC. All rights reserved.
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